Ovarian cancer cell death induced by non-genomic action of progesterone
and its receptor agonist via membrane receptors
Abstract
Background and Aims: Progesterone therapy is a relatively inexpensive
treatment option for endometrial and breast cancers, with few side
effects. Two signaling pathways usually mediate the physiological
effects of progesterone, namely genomic and non-genomic actions. Genomic
action occurs slowly via the nuclear progesterone receptor (PR), whereas
the membrane progesterone receptor (mPR) induces rapid non-genomic
action. We investigated the effects of progesterone and various PR
agonists on ovarian cancer cells. Methods: PR expression of six serous
ovarian cancer cell lines was examined by western blotting, and mPR
expression was examined by RT-qPCR. PR-negative and mPR-positive ovarian
cancer cells were exposed to progesterone and seven types of PR agonists
(medroxyprogesterone acetate [MPA], dehydroepiandrosterone,
dienogest, levonorgestrel, drospirenone, pregnenolone, and
allopregnanolone) at 10–400 μM, and viable cell counts after exposure
for 30 min were measured using the water soluble tetrazolium (WST-1)
assay. Ovarian cancer cell lines were exposed to 100 μM progesterone,
and the expression of BAX, a pro-apoptotic protein, after 1-5 min was
examined by western blotting. Results: Western blotting detected no PR
expression in the six serous ovarian cancer cell lines. In contrast,
RT-qPCR detected mPR expression in all six serous ovarian cancer cell
lines. Progesterone and MPA induced cell death in all tested ovarian
cancer cell lines in a concentration-dependent manner, whereas no effect
was observed for other PR agonists. Western blotting revealed that
pro-apoptotic protein BAX expression occurred 1 min after exposure to
progesterone, suggesting that the cytocidal effects are mediated by
rapid non-genomic action. Conclusions: MPA, like progesterone exhibited
a rapid cytocidal effect on PR-negative ovarian cancer cells through
non-genomic action. Progesterone and MPA could be novel treatment
modalities for ovarian cancer. Keywords: genomics, medroxyprogesterone
acetate, ovarian cancer, progesterone, progesterone receptor